Turning Point Therapeutics Forward Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Apr 26, 2021. Turning Point Therapeutics to Host First Quarter 2021 Conference Call. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. None 2021 2020 2019 2018 2017. Press Release Contact . 12/06/2021 | Press release | Distributed by Public on 12/06/2021 11:43. Contact: Scott Lipman ir@tptherapeutics.com 858-876-3985 Turning Point Therapeutics to Participate in Upcoming Investor Conferences. Contact: Scott Lipman ir@tptherapeutics.com 858-876-3985 All forward-looking statements contained in this press release speak only as of the date on which they were made. PRESS RELEASE PR Newswire . Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. Nov. 9, 2021 Updated: Nov. 9, 2021 4:38 p.m. SAN DIEGO (AP) _ Turning Point Therapeutics Inc. (TPTX) on Tuesday reported a … About Turning Point Therapeutics Inc. ... All forward-looking statements contained in this press release speak only as of the date on which they were made. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. 10628 Science Center Drive Suite 200 San Diego, CA 92121 Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Nov … Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. All forward-looking statements contained in this press release speak only as of the date on which they were made. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Contact: Scott Lipman ir@tptherapeutics.com 858-876-3985 Contact: Scott Lipman ir@tptherapeutics.com 858-876-3985 The information contained in this Current Report … All forward-looking statements contained in this press release speak only as of the date on which they were made. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date … Contact: Scott Lipman ir@tptherapeutics.com 858-876-3985 Transcript Press Release 10-Q EPS of -$1.34 misses by $0.12 | Revenue of $460.00K (-98.16% Y/Y) beats by $460.00K The following slide deck … SAN DIEGO, June 29, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today named Paolo Tombesi as executive vice president and CFO, effective July 26. All forward-looking statements contained in this press release speak only as of the date on which they were made. The company enters 2021 with approximately $1.1 billion in cash, cash equivalents and marketable securities as of Dec. 31, 2020, which is expected to fund operations into 2024. Contact: Scott Lipman ir@tptherapeutics.com 858-876-3985 All forward-looking statements contained in this press release speak only as of the date on which they were made. TURNING POINT THERAPEUTICS, INC. Balance Sheet Data Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Statements contained in this press release regarding matters that are not historical facts are "forward … Find the latest press releases from Turning Point Therapeutics, Inc. Common Stock (TPTX) at Nasdaq.com. Turning Point is made up of decision-makers, but we always act as part of a larger team to drive our mission forward. Want to join us? Our therapies are designed to be different than other cancer medicines, precisely able to target cell signaling processes. Financial. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Contact: Scott Lipman ir@tptherapeutics.com 858-876-3985 Financial. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.Forward-Looking StatementsStatements contained in this … All forward-looking statements contained in this press release speak only as of the date on which they were made. All forward-looking statements contained in this press release speak only as of the date on which they were made. About Turning Point Therapeutics Inc. ... All forward-looking statements contained in this press release speak only as of the date on which they were made. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Contact: Scott Lipman ir@tptherapeutics.com 858-876-3985 Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Year. Turning Point Therapeutics to Participate in Upcoming Investor Conferences. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. SAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next … Contact: Scott Lipman ir@tptherapeutics.com 858-876-3985 Press Release. SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next … Contact: Scott Lipman ir@tptherapeutics.com 858-876-3985 All forward-looking statements contained in this press release speak only as of the date on which they were made. Turning Point Therapeutics does not accept unsolicited referrals or resumes from any source other than directly from candidates. Turning Point Therapeutics Forward Looking StatementsStatements contained in this press release regarding matters that are not historical facts are … ... About Turning Point Therapeutics. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Mr. Tombesi brings 30 years of global financial and accounting experience to … TURNING POINT THERAPEUTICS, INC. Balance Sheet Data (In thousands) (unaudited) All forward-looking statements contained in this press release speak only as of the date on which they were made. Contact: Jim Mazzola jim.mazzola@tptherapeutics.com 858-342-8272. Nov 10, 2021. All forward-looking statements contained in this press release speak only as of the date on which they were made. Turning Point Therapeutics is a clinical-stage precision oncology company with a … Turning Point Therapeutics Reports First-Quarter Financial Results, Provides Operational Updates. All forward-looking statements contained in this press release speak only as of the date on which they were made. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Contact: Scott Lipman ir@tptherapeutics.com 858-876-3985 Blueprint Medicines Corporation (NASDAQ: BPMC ) has agreed to acquire Lengo Therapeutics, a privately held precision oncology company. In 2020, Turning Point completed follow-on stock offerings generating gross proceeds of $374 million and $460 million. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to … About Turning Point Therapeutics Inc. About Turning Point Therapeutics Inc. Lengo Therapeutics ... Cancer Biology & Translational Research at Turning Point Therapeutics where he led the discovery teams which contributed to two new molecular entities, multiple drug combination clinical trials, and the initiation of four drug discovery programs. The company enters 2021 with approximately $1.1 billion in cash, cash equivalents and marketable securities as of Dec. 31, 2020, which is expected to fund operations into 2024. Nov 10, 2021. SAN DIEGO, Calif. and CAMBRIDGE, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision … In 2020, Turning Point completed follow-on stock offerings generating gross proceeds of $374 million and $460 million. Contact: Scott Lipman ir@tptherapeutics.com 858-876-3985 SAN DIEGO and BASEL, Switzerland, Nov. 29, 2021 (GLOBE NEWSWIRE) — Bright Peak Therapeutics, a biotechnology company developing next-generation cytokine immunotherapies to treat cancer and autoimmune disease, today announced that it has appointed Jacob Chacko, M.D., as Chair of its Board of Directors. Such forward-looking statements in this press release include statements regarding, among other things, the efficacy, safety and therapeutic potential of repotrectinib, and the results, conduct, progress and timing of Turning Point Therapeutics’ Phase 1/2 CARE clinical study. All forward-looking statements contained in this press release speak only as of the date on which they were made. Turning Point Therapeutics Reports Third-Quarter Financial Results, Provides Operational Updates. Turning Point Therapeutics Reports Third-Quarter Financial Results, Provides Operational Updates. SAN DIEGO, June 29, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today named Paolo Tombesi as executive vice president and CFO, effective July 26. Mr. Contact: Scott Lipman ir@tptherapeutics.com 858-876-3985 All forward-looking statements contained in this press release speak only as of the date on which they were made. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. A copy of this press release is furnished herewith as Exhibit 99.1. The Investor Relations website contains information about Turning Point Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. All forward-looking statements contained in this press release speak only as of the date on which they were made. Statements contained in this press release regarding matters that are not historical facts are “forward … All forward-looking statements contained in this press release speak only as of the date on which they were made. Contact: Jim Mazzola jim.mazzola@tptherapeutics.com All forward-looking statements contained in this press release speak only as of the date on which they were made. Turning Point Therapeutics: Q3 Earnings Snapshot. Turning Point Brands, Inc. and ReCreation Marketing Announce that ReCreation Marketing Has Changed Its Name to Turning Point Brands Canada SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, will report second quarter financial results following the close of U.S. financial markets on August 9.The company will host a conference call at 1:30 p.m. PT / 4:30 p.m. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. About Turning Point Therapeutics Inc. ET to discuss the … Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. We will not consider unsolicited referrals and/or resumes from vendors including and without limitation, search firms, staffing agencies, fee … Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Press Releases. Item 2.02 Results of Operations and Financial Condition. All forward-looking statements contained in this press release speak only as of the date on which they were made. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Turning Point Therapeutics to Participate in Upcoming Investor Conferences. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Our team is driven by a common goal – to rapidly design and develop new cancer therapies that address unmet medical needs and help make a difference in patients’ lives. Turning Point is made up of decision-makers, but we always act as part of a larger team to drive our mission forward. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. SAN DIEGO, June 29, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today named Paolo Tombesi as executive vice president and CFO, effective July 26. Mr. Tombesi brings 30 years of global financial and accounting experience to Turning Point from multiple … Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. All forward-looking statements contained in this press release speak only as of the date on which they were made. Turning Point Therapeutics. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. About Turning Point Therapeutics Inc. ... All forward-looking statements contained in this press release speak only as of the date on which they were made.
Westside Theatre Stage Door, Celia Pronunciation In Spanish, X-men Days Of Future Past Omar Sy, Mild Cerebral Palsy In Adults, Guelph Storm 2021 Schedule, Was Harambe Protecting The Child, Diana, Princess Of Wales,
